• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, September 20, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

CU Anschutz Medical Campus wins $46.5 million NIH grant to accelerate research discoveries

Bioengineer by Bioengineer
April 25, 2018
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

AURORA, Colo. (April 25, 2018) – The National Institutes of Health (NIH) recently awarded $46.5 million to the University of Colorado Anschutz Medical Campus and its Colorado Clinical and Translational Sciences Institute (CCTSI), a research partnership designed to speed up development of new treatments to address the greatest health needs of Coloradans.

In 2008, the CCTSI was launched with a grant of $76 million–the largest biomedical research and training award in the state's history. This new five-year award brings the total funding from NIH to the CCTSI to more than $187 million.

"The general public may not know the CCTSI name," says Ronald Sokol, MD, CCTSI director and professor of pediatrics in the School of Medicine. "But they have probably benefited from the research that has come out of our institute over the past ten years." Examples include:

  • A cure for hepatitis C, which was made possible in part by dozens of clinical trials that were conducted by CCTSI investigators in our facilities over the past 15 years.
  • Precision medicine treatments for cystic fibrosis that target the defective protein caused by specific gene mutations and which have transformed the lives of patients.
  • Boosting the rates of health screenings that save lives in underserved Colorado communities, such as urban Latino, urban African American and rural eastern Colorado.
  • Decreased mortality rates in five Denver neighborhoods by developing community-based, culturally responsive approaches to tailor educational programs for cardiopulmonary resuscitation (CPR).

"The CCTSI is an engine that has enhanced the research enterprise on the Anschutz Medical Campus for many years," says Dean John J. Reilly, Jr., MD, of the University of Colorado School of Medicine. "We are proud of their work and confident they will continue to provide essential support and leadership for the next generation of physicians and researchers."

Over the next five years, the CCTSI will:

  • Develop, educate and sustain a diverse translational science workforce to ensure the highest research innovation, quality and safety.
  • Create a translational research environment in which team science and collaboration both locally and nationally are facilitated, supported and valued.
  • Engage local and national communities and stakeholders in all phases of the translational research process.
  • Create novel methodologies and resources to support and integrate research in special populations, including children, the elderly, the underserved and those with rare diseases.

"The grant will further establish the University of Colorado Anschutz Medical Campus, and all of our institutional partners, as biomedical research leaders, pioneers and innovators," says Sokol. "We are thrilled to have the opportunity to continue to engage in the full spectrum of translational science to achieve our ultimate goal of getting more treatments to more patients more quickly."

###

The CCTSI is the academic home to help transform the clinical and translational research and training efforts at the University of Colorado Denver | Anschutz Medical Campus University and affiliated institutions. The CCTSI was created in 2008 with funding from the Clinical and Translational Science Award (CTSA) initiative of the National Institutes of Health (NIH) and considerable institutional support. (CCTSI is supported in part by Colorado CTSA Grants UL1TR002535, KL2TR002534 and TL1TR002533 from the National Center for Advancing Translational Sciences/NIH.) The CCTSI includes the University of Colorado Denver, the University of Colorado Boulder, Colorado State University, UCHealth, Children's Hospital Colorado, Denver Health and Hospitals, National Jewish Health, Denver Veterans Affairs Medical Center and Kaiser Foundation Research Institute and local communities.

The University of Colorado Denver | Anschutz Medical Campus is a public research university serving more than 18,000 students and awarding nearly 4,000 degrees each year, including more graduate and professional degrees than any other Colorado institution. With our solid academic reputation, award-winning faculty and renowned researchers, we offer more than 140 highly rated degree programs through 13 schools and colleges. A national leader in health care and life sciences, CU Anschutz is the only comprehensive academic health sciences center in Colorado and the largest in the Rocky Mountain region. Located in Aurora, Colo., it is one of the newest education, research and patient care facilities in the world. The University of Colorado Anschutz Medical Campus ranks among the top institutions nationally in clinical care, education and research. A hub for research and innovation, CU Anschutz receives over $400 million in research awards each year and has filed 1,300 patent applications and formed 53 new companies since 2002.

Media Contact

Mark Couch
[email protected]
303-724-5377
@CUAnschutz

http://www.ucdenver.edu

Share12Tweet7Share2ShareShareShare1

Related Posts

Impact of Defect Size and Location on Spinal Fractures

September 20, 2025

Low PDA Shunt Linked to Premature Infant Risks

September 20, 2025

Hydrocortisone Use in Extremely Preterm Infants

September 20, 2025

Revolutionizing Nine Hole Peg Test with Computer Vision

September 20, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    156 shares
    Share 62 Tweet 39
  • Physicists Develop Visible Time Crystal for the First Time

    67 shares
    Share 27 Tweet 17
  • Tailored Gene-Editing Technology Emerges as a Promising Treatment for Fatal Pediatric Diseases

    49 shares
    Share 20 Tweet 12
  • Scientists Achieve Ambient-Temperature Light-Induced Heterolytic Hydrogen Dissociation

    48 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Caffeine Exposure Shapes Neurodevelopment in Premature Infants

Impact of Defect Size and Location on Spinal Fractures

New Metabolic Syndrome Score Validated in Teens

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.